INTRODUCTION: Previous studies have demonstrated the possibility of detecting K mutations in the plasma of patients with pancreatic carcinoma. AIM: To investigate the diagnostic value of combined plasma K mutations with serum CA19-9 in patients with pancreatic carcinoma. METHODOLOGY: The study included 58 consecutive patients with suspected pancreatic masses and 21 healthy controls. DNA was extracted from plasma. Point mutation at codon 12 of K gene was analyzed by means of the enriched polymerase chain reaction-restriction fragment length polymorphism technique. RESULTS: No mutated K codon 12 was detected in the plasma DNA from the 21 healthy controls. Mutations of K codon 12 were found in plasma DNA samples from 29 (70.7%) of 41 patients with pancreatic carcinoma. Elevated CA19-9 was found in 30 (73.2%) of 41 pancreatic cancer patients. In total, 37 of 41 (90.2%) patients with pancreatic carcinoma tested positive by either method. Mutated K was also found in 3 patients and elevated CA19-9 in 8 of the 17 patients with other lesions in the pancreatic area. CONCLUSION: The results indicate that plasma K mutation analysis combined with serum CA19-9 determination could detect the majority of cases of pancreatic carcinoma.
INTRODUCTION: Previous studies have demonstrated the possibility of detecting K mutations in the plasma of patients with pancreatic carcinoma. AIM: To investigate the diagnostic value of combined plasma K mutations with serum CA19-9 in patients with pancreatic carcinoma. METHODOLOGY: The study included 58 consecutive patients with suspected pancreatic masses and 21 healthy controls. DNA was extracted from plasma. Point mutation at codon 12 of K gene was analyzed by means of the enriched polymerase chain reaction-restriction fragment length polymorphism technique. RESULTS: No mutated K codon 12 was detected in the plasma DNA from the 21 healthy controls. Mutations of K codon 12 were found in plasma DNA samples from 29 (70.7%) of 41 patients with pancreatic carcinoma. Elevated CA19-9 was found in 30 (73.2%) of 41 pancreatic cancerpatients. In total, 37 of 41 (90.2%) patients with pancreatic carcinoma tested positive by either method. Mutated K was also found in 3 patients and elevated CA19-9 in 8 of the 17 patients with other lesions in the pancreatic area. CONCLUSION: The results indicate that plasma K mutation analysis combined with serum CA19-9 determination could detect the majority of cases of pancreatic carcinoma.
Authors: Julia A Beaver; Danijela Jelovac; Sasidharan Balukrishna; Rory Cochran; Sarah Croessmann; Daniel J Zabransky; Hong Yuen Wong; Patricia Valda Toro; Justin Cidado; Brian G Blair; David Chu; Timothy Burns; Michaela J Higgins; Vered Stearns; Lisa Jacobs; Mehran Habibi; Julie Lange; Paula J Hurley; Josh Lauring; Dustin VanDenBerg; Jill Kessler; Stacie Jeter; Michael L Samuels; Dianna Maar; Leslie Cope; Ashley Cimino-Mathews; Pedram Argani; Antonio C Wolff; Ben H Park Journal: Clin Cancer Res Date: 2014-02-06 Impact factor: 12.531
Authors: K Allenson; J Castillo; F A San Lucas; G Scelo; D U Kim; V Bernard; G Davis; T Kumar; M Katz; M J Overman; L Foretova; E Fabianova; I Holcatova; V Janout; F Meric-Bernstam; P Gascoyne; I Wistuba; G Varadhachary; P Brennan; S Hanash; D Li; A Maitra; H Alvarez Journal: Ann Oncol Date: 2017-04-01 Impact factor: 32.976
Authors: Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill Journal: Curr Mol Med Date: 2013-03 Impact factor: 2.222